RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical firm centered on growing medicines to focus on hypertension and associated comorbidities equivalent to power kidney illness (CKD), obstructive sleep apnea (OSA) and different illnesses pushed by dysregulated aldosterone, introduced at present that on March 16, 2026, the Compensation Committee of Mineralys’ Board of Administrators granted an inducement inventory choice award protecting 27,920 shares and an inducement restricted inventory unit award protecting 20,940 shares of Mineralys widespread inventory to a brand new non-executive worker.
The awards had been granted below Mineralys’ 2025 Employment Inducement Incentive Award Plan, which supplies for the granting of fairness awards to new workers of Mineralys. The choices will vest over a four-year interval, with 25% of the overall shares underlying the choices vesting on the primary anniversary of the award’s vesting graduation date, March 16, 2026, and 1/forty eighth of the overall shares underlying the choice vesting following every one-month interval thereafter, topic to continued service. The restricted inventory items will vest over a four-year interval, with 25% of the shares vesting on every of the 4 anniversaries of the award’s vesting graduation date, March 16, 2026. The awards had been granted as an inducement materials to the brand new non-executive worker getting into into employment with Mineralys, in accordance with Nasdaq Itemizing Rule 5635(c)(4).
About Mineralys
Contact:
Investor Relations
